Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis

Cell Research

Volumn 22, Issue 9, 2012, Pages 1356-1373

  Jin, Lei ^a   Zhang, Yan ^b   Li, Hui ^a   Yao, Ling ^b   Fu, Da ^a   Yao, Xuebiao ^c   Xu, Lisa X ^b   Hu, Xiaofang ^b   Hu, Guohong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

bone metastasis; breast cancer; CST6; cystatin; proteomics; secretome

Indexed keywords

CYSTATIN M; PROTEOME; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; BONE TUMOR; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; METASTASIS; MORTALITY; MOUSE; PATHOLOGY; PROTEOMICS; RNA INTERFERENCE; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTATIN M; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PROTEOME; PROTEOMICS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY;

ANIMALIA; MUS;

EID: 84865763229     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.90     Document Type: Article

References (75)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106:1624-1633.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593. (Pubitemid 37328925)
4. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011; 7:208-218.
5. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med 2008; 6:52.
6. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128:2527-2535.
7. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56. (Pubitemid 32225831)
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124:263-266. (Pubitemid 43121975)
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174. (Pubitemid 37328786)
10. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005; 52:1-9.
11. Yang SY, Miah A, Pabari A, Winslet M. Growth Factors and their receptors in cancer metastases. Front Biosci 2011; 16:531-538.
12. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438:820-827. (Pubitemid 41753060)
13. Caccia D, Zanetti Domingues L, Micciche F, et al. Secretome compartment is a valuable source of biomarkers for cancerrelevant pathways. J Proteome Res 2011; 10:4196-4207.
14. Zhong L, Roybal J, Chaerkady R, et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 2008; 68:7237-7245.
15. Kashyap MK, Harsha HC, Renuse S, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 2010; 10:796-810.
16. Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006; 5:157-171. (Pubitemid 43169348)
17. Wu CC, Hsu CW, Chen CD, et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010; 9:1100-1117.
18. Weng LP, Wu CC, Hsu BL, et al. Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J Proteome Res 2008; 7:3765-3775.
19. Ohanna M, Giuliano S, Bonet C, et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 2011; 25:1245-1261.
20. Chang YT, Wu CC, Shyr YM, et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One 2011; 6:e20029.
21. Kreunin P, Urquidi V, Lubman DM, Goodison S. Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 2004; 4:2754-2765. (Pubitemid 39202175)
22. Rocco M, Malorni L, Cozzolino R, et al. Proteomic profiling of human melanoma metastatic cell line secretomes. J Proteome Res 2011; 10:4703-4714.
23. Mbeunkui F, Metge BJ, Shevde LA, Pannell LK. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 2007; 6:2993-3002. (Pubitemid 47310184)
24. Xue H, Lu B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010; 9:545-555.
25. Wang CL, Wang CI, Liao PC, et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res 2009; 8:4428-4440.
26. Chiu KH, Chang YH, Wu YS, Lee SH, Liao PC. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J Proteome Res 2011; 10:1110-1125.
27. Ween MP, Lokman NA, Hoffmann P, et al. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 2011; 128:1570-1584.
28. Rondepierre F, Bouchon B, Bonnet M, et al. B16 melanoma secretomes and in vitro invasiveness: syntenin as an invasion modulator. Melanoma Res 2010; 20:77-84.
29. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-549. (Pubitemid 36808649)
30. Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009; 15:960-966.
31. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19:192-205.
32. Serganova I, Moroz E, Vider J, et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J 2009; 23:2662-2672.
33. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115:44-55. (Pubitemid 40385504)
34. Ganapathy V, Ge R, Grazioli A, et al. Targeting the Transforming Growth Factor-beta pathway inhibits human basallike breast cancer metastasis. Mol Cancer 2010; 9:122.
35. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545-15550. (Pubitemid 41528093)
36. Ochieng J, Chaudhuri G. Cystatin superfamily. J Health Care Poor Underserved 2010; 21(1 Suppl):51-70.
37. Lu X, Mu E, Wei Y, et al. VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging alpha4beta1-Positive Osteoclast Progenitors. Cancer Cell 2011; 20:701-714.
38. Ai L, Kim WJ, Kim TY, et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res 2006; 66:7899-7909. (Pubitemid 44299152)
39. Rivenbark AG, Jones WD, Coleman WB. DNA methylationdependent silencing of CST6 in human breast cancer cell lines. Lab Invest 2006; 86:1233-1242. (Pubitemid 44789913)
40. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123:725-731.
41. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16:67-78.
42. Zhang J, Shridhar R, Dai Q, et al. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res 2004; 64:6957-6964. (Pubitemid 39331005)
43. Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol 2007; 83:188-197. (Pubitemid 47320656)
44. Cheng T, van Vlijmen-Willems IM, Hitomi K, et al. Colocalization of cystatin M/E and its target proteases suggests a role in terminal differentiation of human hair follicle and nail. J Invest Dermatol 2009; 129:1232-1242.
45. Sotiropoulou G, Anisowicz A, Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem 1997; 272:903-910. (Pubitemid 27034580)
46. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-524. (Pubitemid 41112921)
47. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459:1005-1009.
48. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23:1882-1894.
49. Giles ED, Singh G. Role of insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis. Clin Exp Metastasis 2003; 20:481-487. (Pubitemid 37297175)
50. Ye L, Bokobza SM, Jiang WG. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 2009; 24:591-597.
51. Shen Y, Winkler IG, Barbier V, et al. Tissue inhibitor of metalloproteinase-(TIMP-3) regulates hematopoiesis and bone formation in vivo. PLoS One 2010; 5:e13086.
52. Yoon KJ, Phelps DA, Bush RA, et al. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS One 2008; 3:e3629.
53. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291:113-135. (Pubitemid 30089760)
54. Tseng MY, Liu SY, Chen HR, et al. Serine protease inhibitor (SERPIN) B1 promotes oral cancer cell motility and is overexpressed in invasive oral squamous cell carcinoma. Oral Oncol 2009; 45:771-776.
55. Krepela E, Prochazka J, Karova B, Cermak J, Roubkova H. Cysteine proteases and cysteine protease inhibitors in nonsmall cell lung cancer. Neoplasma 1998; 45:318-331. (Pubitemid 29010682)
56. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392. (Pubitemid 34270240)
57. Bialas A, Kafarski P. Proteases as anti-cancer targets-molecular and biological basis for development of inhibitorlike drugs against cancer. Anticancer Agents Med Chem 2009; 9:728-762.
58. Zeeuwen PL, van Vlijmen-Willems IM, Cheng T, et al. The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea. FASEB J 2010; 24:3744-3755.
59. Zeeuwen PL, van Vlijmen-Willems IM, Hendriks W, Merkx GF, Schalkwijk J. A null mutation in the cystatin M/E gene of ichq mice causes juvenile lethality and defects in epidermal cornification. Hum Mol Genet 2002; 11:2867-2875.
60. Pulukuri SM, Gorantla B, Knost JA, Rao JS. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene 2009; 28:2829-2838.
61. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66:7490-7501. (Pubitemid 44289203)
62. Veena MS, Lee G, Keppler D, et al. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer 2008; 47:740-754.
63. Morris MR, Ricketts C, Gentle D, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010; 29:2104-2117.
64. Vigneswaran N, Wu J, Nagaraj N, et al. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sci 2006; 78:898-907. (Pubitemid 43082316)
65. Briggs JJ, Haugen MH, Johansen HT, et al. Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer 2010; 10:17.
66. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 2006; 235:159-176.
67. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24:227-235. (Pubitemid 30132189)
68. Sellappan S, Grijalva R, Zhou X, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004; 64:3479-3485. (Pubitemid 38657921)
69. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004; 21:543-552.
70. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007; 104:13-19. (Pubitemid 46976633)
71. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009; 69:5292-5293.
72. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase database. Nucleic Acids Res 2010; 38 (Database issue):D227-233.
73. Yao L, Zhang Y, Chen K, Hu X, Xu LX. Discovery of IL-18 As a Novel Secreted Protein Contributing to Doxorubicin Resistance by Comparative Secretome Analysis of MCF-7 and MCF-7/Dox. PLoS One 2011; 6:e24684.
74. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004; 340:783-795. (Pubitemid 38829638)
75. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 2004; 17:349-356. (Pubitemid 39093515)